Combination of fractional carbon dioxide laser with narrow band ultraviolet B to induce repigmentation in stable vitiligo: A comparative study.

Autor: Doghaim NN; Faculty of Medicine, Department of Dermatology and Venereology, Tanta University, Tanta, Egypt., Gheida SF; Faculty of Medicine, Department of Dermatology and Venereology, Tanta University, Tanta, Egypt., El-Tatawy RA; Faculty of Medicine, Department of Dermatology and Venereology, Tanta University, Tanta, Egypt., Mohammed Ali DA; Faculty of Medicine, Pathology Department, Tanta University, Tanta, Egypt.
Jazyk: angličtina
Zdroj: Journal of cosmetic dermatology [J Cosmet Dermatol] 2019 Feb; Vol. 18 (1), pp. 142-149. Date of Electronic Publication: 2018 Apr 30.
DOI: 10.1111/jocd.12553
Abstrakt: Background: Despite the numerous treatment modalities available for vitiligo, responses to treatment are still unsatisfactory. For this reason, new treatment modalities and approaches are needed.
Objective: To evaluate the efficacy and safety of fractional carbon dioxide (CO 2 ) laser therapy followed by narrow band ultraviolet-B (NB-UVB) phototherapy on stable resistant vitiligo.
Subjects and Methods: Thirty-two patients with stable bilateral vitiligo were enrolled. For each patient, one side of the body was treated with NB-UVB in addition to two sessions of fractional CO 2 laser performed at 2-months interval (laser side), while the other side was treated with NB-UVB alone (control side). NB-UVB was administrated twice weekly for 4 months. Outcomes were evaluated objectively based on standard digital photographs, patient satisfaction, and adverse effects.
Results: There was statistically significant improvement in the repigmentation in laser side compared to control side. Noticeable adverse events, such as infection, scarring, and Koebner phenomenon were not found in any patient.
Conclusions: Fractional CO 2 laser therapy combined with NB-UVB phototherapy could be used effectively and safely as an alternative modality for the treatment of vitiligo. It shortens the duration of NB-UVB therapy and is expected to increase patient compliance.
(© 2018 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje